NephCure reposted this
Today, we are pleased to announce a positive outcome with the U.S. FDA in our investigational drug program meeting, which studies the potential treatment for those living with Immunoglobulin A nephropathy (IgA nephropathy) in adults. Following the meeting, Otsuka will submit a Biologics License Application (BLA) for FDA consideration in early 2025. At Otsuka, our continued work in nephrology is fueled by a relentless curiosity and a promise to ensure that patient populations with high unmet needs receive the most advanced nephrology care possible. Read more: https://bit.ly/494tRzC